Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
999 studies found for:    Open Studies | "Antineoplastic Agents, Alkylating"
Show Display Options
Rank Status Study
1 Not yet recruiting Disulfiram in Recurrent Glioblastoma
Conditions: Glioma;   Glioblastoma
Interventions: Drug: Disulfiram;   Dietary Supplement: Copper;   Drug: Alkylating Agents
2 Recruiting PTCy and Ruxolitinib GVHD Prophylaxis in Myelofibrosis
Conditions: Primary Myelofibrosis;   Myeloproliferative Disorders
Interventions: Procedure: Allogeneic hematopoietic stem cell transplantation;   Drug: Busulfan;   Drug: Fludarabine monophosphate;   Drug: Cyclophosphamide;   Drug: Ruxolitinib
3 Recruiting Randomized Study of Combination Chemotherapy With or Without Focused Microwave Thermotherapy Before Surgery in Treating Women With Large Breast Cancer Tumors
Condition: Breast Cancer
Interventions: Device: Focused Microwave Thermotherapy;   Drug: Chemotherapy (control)
4 Recruiting GVHD Prophylaxis With Post-transplantation Bendamustine in Refractory Leukemia
Conditions: Leukemia, Acute Lymphoblastic;   Acute Myeloid Leukemia;   Mixed-Lineage Acute Leukemias
Interventions: Procedure: Allogeneic stem cell transplantation;   Drug: Fludarabine monophosphate;   Drug: Busulfan;   Drug: Bendamustine
5 Recruiting Denintuzumab Mafodotin (SGN-CD19A) Combined With RCHOP or RCHP Versus RCHOP Alone in Diffuse Large B-Cell Lymphoma or Follicular Lymphoma
Conditions: Diffuse, Large B-Cell, Lymphoma;   Follicular Lymphoma, Grade 3b;   Transformed Lymphoma / DLBCL
Interventions: Drug: denintuzumab mafodotin;   Drug: rituximab;   Drug: cyclophosphamide;   Drug: doxorubicin;   Drug: vincristine;   Drug: prednisone
6 Recruiting Trial of GVHD Prophylasxis With PTCy or Thymoglobulin in Unrelated SCT
Conditions: Leukemia, Chronic Myeloid;   Myelodysplastic Syndromes;   Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative
Interventions: Procedure: Unrelated allogeneic stem cell transplantation;   Drug: Busulfan;   Drug: Fludarabine monophosphate;   Drug: Tacrolimus;   Drug: Mycophenolate mofetil;   Drug: Cyclophosphamide;   Drug: Thymoglobulin
7 Not yet recruiting INdividualized Screening Trial of Innovative Glioblastoma Therapy (INSIGhT)
Condition: Glioblastoma
Interventions: Drug: Temozolomide;   Drug: Neratinib;   Drug: CC-115;   Drug: Abemaciclib
8 Not yet recruiting Autologous Stem Cell Collection and Reinfusion in Newly Diagnosed High Grade Gliomas
Conditions: Astrocytoma;   Brainstem Glioma;   Ependymoma;   Mixed Glioma;   Oligodendroglioma;   Optic Nerve Glioma
Interventions: Radiation: Radiation therapy;   Drug: Temozolomide;   Procedure: Stem cell collection;   Procedure: Stem cell infusion
9 Not yet recruiting Expedited Laser Interstitial Thermal Therapy + Chemoradiation For Newly Diagnosed High Grade Gliomas
Condition: High Grade Glioma
Interventions: Procedure: LITT;   Radiation: Radiation therapy;   Drug: Temozolomide
10 Recruiting TG02 Plus Dose-Dense or Metronomic Temozolomide Followed by Randomized Phase II Trial of TG02 Plus Temozolomide Versus Temozolomide Alone in Adults With Recurrent Anaplastic Astrocytoma and Glioblastoma
Conditions: Brain Tumor;   Astrocytoma;   Astroglioma;   Glioblastoma;   Gliosarcoma
Interventions: Drug: TG02;   Drug: TMZ
11 Not yet recruiting Trabectedin Maintenance Post 1st-line in STS
Condition: Sarcoma, Soft Tissue
Intervention: Drug: Trabectedin
12 Recruiting Regorafenib in Relapsed Glioblastoma
Condition: Glioblastoma Multiforme
Interventions: Drug: Regorafenib;   Drug: Lomustine
13 Not yet recruiting A Study of Obinutuzumab Evaluating Efficacy, Safety and Cost of Disease Management in Participants With Chronic Lymphocytic Leukemia and Comorbidities
Condition: Chronic Lymphocytic Leukemia
Interventions: Drug: Chlorambucil;   Drug: Obinutuzumab
14 Recruiting Study of Marizomib With Temozolomide and Radiotherapy in Patients With Newly Diagnosed Brain Cancer
Conditions: Glioblastoma;   Malignant Glioma
Interventions: Drug: MRZ;   Drug: TMZ;   Radiation: RT
15 Not yet recruiting Phase 1 Two Part Dose Escalation Trial of RRx-001 + Radiation + Temozolomide and RRx-001 + Temozolomide Post-RT In Newly Diagnosed Glioblastoma and Anaplastic Gliomas
Conditions: Glioblastoma;   Oligodendroglioma;   Anaplastic Oligodendroglioma
Interventions: Drug: RRx-001 dose escalation with TMZ + RT;   Radiation: Radiation;   Drug: Fixed dose Temozolomide (75 mg/m2);   Drug: Fixed RRx-001 weekly;   Drug: Staged TMZ and RRx-001 escalation in maintenance stage;   Drug: TMZ Maintenance
16 Not yet recruiting Peptide Targets for Glioblastoma Against Novel Cytomegalovirus Antigens
Conditions: Glioblastoma;   Glioblastoma Multiforme
Interventions: Drug: 5-day TMZ;   Drug: 21-day TMZ;   Biological: PEP-CMV;   Drug: Tetanus-Diphtheria booster;   Drug: Tetanus Pre-Conditioning
17 Recruiting Study to Evaluate the Efficacy, Safety, Pharmacokinetics and Pharmacodynamic Effects of PQR309 in Glioblastoma Patients
Condition: Glioblastoma Multiforme
Intervention: Drug: PQR309
18 Not yet recruiting A Clinical Trial on Whole-brain Radiotherapy With Temozolomide Concurrent Chemotherapy or Avoidance of Hippocampus for Patients of Brain Metastases
Conditions: Brain Metastasis;   Radiation Therapy Complication
Interventions: Drug: TMZ;   Radiation: WBRT with avoidance of hippocampus;   Radiation: WBRT without avoidance of hippocampus
19 Recruiting Non-interventional European Study of Trabectedin + PLD in the Treatment of Relapsed Ovarian Cancer (ROC) Patients
Condition: Relapsed Ovarian Cancer
Intervention: Drug: trabectedin
20 Not yet recruiting A Study of High-Dose Chemoradiation Using Biologically-Based Target Volume Definition in Patients With Glioblastoma
Condition: Glioma
Interventions: Radiation: High Dose Radiation;   Drug: Temozolomide

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.